OrsoBio Funding: $127M Raised, Series B (2024)

OrsoBio funding overview

OrsoBio is based in Palo Alto, CA. OrsoBio has raised $127M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in September 2024. The round record for OrsoBio runs through 2024; nothing later has been disclosed. Investors on record include Eli Lilly and Company, Enavate Sciences, Longitude Capital, NuevaBio, Samsara BioCapital, Ascenta Capital and 1 others. 7 distinct backers are named across the disclosed rounds.

OrsoBio at a glance

Total raised: $127M
Latest round: Series B
Latest round date: September 2024
Headquarters: Palo Alto, CA
Notable investors: Eli Lilly and Company, Enavate Sciences, Longitude Capital, NuevaBio, Samsara BioCapital, Ascenta Capital, Woodline Partners

Frequently asked about OrsoBio funding

How much has OrsoBio raised?: OrsoBio has raised $127M in total disclosed funding across the rounds on record.
Who has invested in OrsoBio?: Eli Lilly and Company, Enavate Sciences, Longitude Capital, NuevaBio, Samsara BioCapital, Ascenta Capital are named among the investors backing OrsoBio.
What was the latest OrsoBio funding round?: The most recent disclosed round is a Series B, announced in September 2024.
Where is OrsoBio based?: OrsoBio is based in Palo Alto, CA.
When did OrsoBio last raise?: The last disclosed OrsoBio round closed in September 2024 at Series B.

OrsoBio totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Palo Alto below to benchmark round size and investor mix.

OrsoBio Funding: $127M Raised, Series B (2024)

OrsoBio funding overview

OrsoBio at a glance

Frequently asked about OrsoBio funding

Companies related to OrsoBio (36)

Browse related funding lists (8)